CME Presentations
Melanoma
Presentations
Applying a Patient-centered Approach to Unresectable and Metastatic Melanoma
Duration: 60 minutes
Presented on: February 13, 2023
Speakers
Megan Schollenberger, MSN, CRNP
Megan Schollenberger, MSN, CRNP
Senior Nurse Practitioner, Medical Oncology
Megan Schollenberger, MSN, CRNP, is a Senior Nurse Practitioner in medical oncology at Johns Hopkins who focuses on cutaneous malignancies. Ms. Schollenberger has over a decade of patient care experience, including as an inpatient leukemia nurse, an outpatient primary care nurse practitioner, and in her current role at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Her primary clinical interest is in the holistic treatment of patients with advanced skin cancers, including melanoma and basal, cutaneous squamous, and Merkel cell carcinomas. Furthermore, Ms. Schollenberger is a co-investigator on multiple clinical trials testing novel immunomodulatory therapies for patients with cutaneous malignancies and a co-author on multiple abstracts and publications.
Omid Hamid, MD
Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Omid Hamid, MD, is Chief, Translational Research and Immunotherapy and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute. As Director, he works to ensure that patients receive access to the most up-to-date therapeutics. Dr. Hamid’s research focus involves manipulation of a patient’s immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies. His research began in melanoma and has now extended into paradigm shifting trials for all cancers. Recently, Dr. Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. Furthermore, he is recognized internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics.
Evan Lipson, MD
Evan Lipson, MD
Associate Professor, Medical Oncology
Evan Lipson, MD, is a cutaneous oncology and clinical immunotherapy specialist and Associate Professor of Oncology at Johns Hopkins. Dr. Lipson's primary research interest is in translational clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer and the first description of kidney retransplantation performed after anti–PD-1–related allograft rejection. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy.
CME Information
Applying a Patient-centered Approach to Unresectable and Metastatic MelanomaJointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC in collaboration with the Melanoma Action Coalition (MAC).
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.DATE OF RELEASE/EXPIRATION
This activity was released on February 13, 2023 and is valid until February 13, 2024. Requests for credit must be made no later than February 13, 2024.TARGET AUDIENCE
The educational design of this activity addresses the needs of medical oncologists, dermatologic oncologists, dermatologists, surgical oncologists, dermatologic surgeons, surgeons, oncology nurse practitioners, oncology/dermatology nurses, and physician assistants, and other clinicians involved in the management of patients with melanoma.STATEMENT OF NEED/PROGRAM OVERVIEW
Recent advances in immunotherapies for melanoma provide additional treatment options for patients with unresectable locally advanced or metastatic melanoma. However, the evolving therapeutic landscape and complex process of treatment selection make it difficult for clinicians to individualize and optimize the management of each patient.
Join a dermatologic oncologist and medical oncologist to discuss the latest advances in the diagnosis and treatment of advanced melanoma. Panelists will review how to identify appropriate mono or combination immunotherapies for individual patients who do not have surgery as an option. The experts will also look at appropriate timing of therapy, treatment-associated adverse events, and how to engage patients in shared decision-making.
Do you have patients with melanoma who could benefit from education on the use of immunotherapies and strategies to maintain quality of life? Direct your patients to CancerCoachLive.com to access the activity, “Partnering with Your Team to Select Treatment for Newly Diagnosed Melanoma.”EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Evaluate efficacy data from practice-changing clinical trials on new and emerging immunotherapies for unresectable and metastatic melanoma
- Outline adverse events associated with immunotherapies and approaches to mitigate these effects while optimizing management of patients with advanced melanoma
- Review guideline-based treatment approaches for advanced melanoma and the rationales for new mechanisms of action and combination therapies
- Discuss strategies to individualize treatment plans for patients with melanoma through multidisciplinary care and shared decision-making
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Faculty Conflicts of Interest Omid Hamid, MD
Chief of Research/Immuno-Oncology
The Angeles Clinic & Research Institute
Co-Director, Cutaneous Malignancy Program
Cedars-Sinai Cancer
Consultant, Advisor, and Speaker: Alkermes; Amgen; Bactonix; Beigene; Bioatla; Bristol Myers Squibb; Esai; Roche Genentech; Georgiamune; GigaGen; Grit Bio; GlaxoSmithKline; ldera; lmmunocore; lncyte; lnstilbio; lovance; Janssen; KSQ; Merck; Moderna; Novartis; Obsidian; Pfizer; Regeneron; Seattle Genetics; Tempus; Vial Health Tech; and Zelluna.
Contracted Research: Arcus; Aduro; Akeso; Amgen; Bioatla; Bristol Myers Squibb; Cytomx; Exelixis; Roche Genentech; GlaxoSmithKline; lmmunocore; ldera; lncyte; lovance; Merck; Moderna; Merck Serono; Nextcure; Novartis; Pfizer; Regeneron; Seattle Genetics; and Zelluna.Evan J. Lipson, MD
Associate Professor, Medical Oncology
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Consultant/Honoraria: Bristol-Myers Squibb; CareDX; Eisai; Genentech; HUYA Bioscience International; Immunocore; Instil Bio; MacroGenics; Merck; Natera; Nektar; Novartis; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Replimune; and Sanofi.
Institutional Research Funding: Bristol-Myers Squibb; Merck; Regeneron; and Sanofi.Megan Schollenberger, MSN, CRNP
Senior Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
No relevant financial relationships to disclose
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For additional information about the accreditation of this activity, please visit https://partnersed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
